Drugs / Bivalent BA.4/5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05925127 | Oct 2023 → May 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent BA.4/5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05925127 ↗ |
| Modality | Messenger RNA (mRNA) | “licensed mRNA vaccine” NCT05925127 ↗ |
| Route | Intramuscular | “single IM injection” NCT05925127 ↗ |